European pharmaceutical companies are sounding alarm bells regarding potential tariffs imposed by the Trump administration, warning that these could lead to a significant exodus of the industry to the United States. CEOs from major pharma firms have urged the European Commission and President Ursula von der Leyen to take action and negotiate with US officials to avoid escalating trade tensions. The looming tariffs, estimated to cost the EU over $100 billion, have prompted a dialogue between industry leaders and EU officials in hopes of shielding the sector from detrimental effects. As concerns grow, there are calls for reforms within the EU to retain innovation and investment in the pharmaceutical industry.